EKR Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EKR Therapeutics Inc.
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.
The Swiss company's asthma triplet is now approved in Europe and Japan but Enerzair is well behind GSK's rival LABA/LAMA/ICS in the US where Novartis's product has not even been submitted yet.
Otonomy, a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for diseases and disorders of the inner and middle ear, has named Anthony J Yost chief commercial officer. Most recently Mr Yost was chief commercial officer for specialty pharma companies Prometheus Laboratories and EKR Therapeutics. Prior to this he was general manager for the Western US operating unit of Novartis Pharmaceuticals, where he led commercial operations totaling more than 600 employees generating annual revenues in excess of $600m.
Cornerstone Therapeutics formed a special committee with five independent directors to develop a response to the Cary, North Carolina-based company's largest shareholder – the Chiesi Group of Parma, Italy – which wants to acquire the 40% of Cornerstone stock that it does not already own and take the US firm private.